glp-1 market news Receptor Agonist Size & Share Report, 2032 GLP-1 Receptor Agonist Market Size

doi: 10.2337/dc25-S013 37 DasSREverettBMBirtcherKKBrownJMJanuzziJLKalyaniRRet al

R.JonesN

A GLP-1/glucagon (GCG)/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes

Compared to older GLP-1 medications, Ozempic typically produces better weight loss outcomes, with many patients seeing a reduction of 10-15% of their body weight over several months of treatment

This includes synapse formation and maturation, ion and neurotransmitter homeostasis, blood-brain barrier maintenance, and neuronal metabolic support [12,13]

Dark Urine on Ozempic: Causes, Safety and When to Seek Help Dark urine on Ozempic (semaglutide) concerns many patients, though it is not listed as a common side effect in UK regulatory documentation